Stockscreener 앱 받기
0.9178
0.90%
0.0082
시간 외 거래:
.91
-0.0078
-0.85%
전일 마감가:
$0.9096
열려 있는:
$0.91
하루 거래량:
1.70M
Relative Volume:
0.77
시가총액:
$145.61M
수익:
$3,000
순이익/손실:
$-140.95M
주가수익비율:
-0.4488
EPS:
-2.0449
순현금흐름:
$-90.89M
1주 성능:
+12.32%
1개월 성능:
+48.03%
6개월 성능:
-37.99%
1년 성능:
-49.01%
1일 변동 폭
$0.866
$0.9199
1주일 범위
$0.795
$0.95
52주 변동 폭
$0.3772
$3.03
Fractyl Health Inc Stock (GUTS) Company Profile
명칭
Fractyl Health Inc
전화
781-902-8800
주소
3 VAN DE GRAAFF DRIVE, BURLINGTON
Compare GUTS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
0.9178 | 144.31M | 3,000 | -140.95M | -90.89M | -2.0449 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-15 | 개시 | H.C. Wainwright | Buy |
| 2025-08-28 | 개시 | Ladenburg Thalmann | Buy |
| 2024-02-28 | 개시 | Evercore ISI | Outperform |
| 2024-02-27 | 개시 | BofA Securities | Buy |
| 2024-02-27 | 개시 | Morgan Stanley | Overweight |
모두보기
Fractyl Health Inc 주식(GUTS)의 최신 뉴스
Fractyl Health Q1 earnings call highlights - MSN
GUTS - Intellectia AI
Fractyl Health’s Pivotal Year: Inside the Earnings Call - TipRanks
Earnings call transcript: Fractyl Health Q1 2026 reports EPS beat, shares surge - Investing.com
Fractyl targets early Q4 2026 REMAIN-1 pivotal readout amid plans for late Q4 2026 de novo submission - MSN
Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround - Yahoo Finance
First human GLP-1 gene therapy trial gets green light - The Hill
Nantahala’s 16.1M-share stake disclosed in Fractyl Health (NASDAQ: GUTS) - Stock Titan
[SCHEDULE 13G/A] FRACTYL HEALTH, INC. Amended Passive Investment Disclosure - Stock Titan
BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating, Announces Target Price $2 - Moomoo
Fractyl Health (GUTS) stock jumps 21% after hours: Here's what you should know - MSN
TradingKey - TradingKey
A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), UnitedHealth (UNH) and TELA Bio (TELA) - The Globe and Mail
GUTS Stock Chart | FRACTYL HEALTH INC (NASDAQ:GUTS) - ChartMill
SilverArc and Devesh Gandhi report 3.6M shares in Fractyl Health (GUTS) - Stock Titan
Fractyl Health | 10-Q: Q1 2026 Earnings Report - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Morgan Stanley Maintains Fractyl Health(GUTS.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Earnings call transcript: Fractyl Health Q1 2026 sees EPS beat, stock rises By Investing.com - Investing.com India
Fractyl Health Q1 2026 Earnings Call Transcript - MarketBeat
Fractyl Health Q1 Earnings Call Highlights - sharewise.com
Earnings call transcript: Fractyl Health Q1 2026 sees EPS beat, stock rises - Investing.com
Fractyl Health Q1 2026 Earnings Call: Complete Transcript - Benzinga
Fractyl Health Inc (NASDAQ:GUTS) Q1 Earnings: Net Income Swing Masks Core Operating Burn as Key Revita Data Readout Looms - ChartMill
FRACTYL HEALTH ($GUTS) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates - The Manila Times
Fractyl Health 1Q 2026: Net income $9.22M, EPS $0.06— 10-Q Summary - TradingView
Fractyl Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fractyl Health (NASDAQ: GUTS) posts Q1 2026 profit but flags going concern risk - Stock Titan
Fractyl Health (Nasdaq: GUTS) Q1 2026 results, Revita pivotal and Rejuva CTA - Stock Titan
Fractyl Health’s RJVA-001 cleared to enter clinic in Netherlands - BioWorld News
GUTS EarningsMAR/2026 AI PredictionIntellectia AI™ - Intellectia AI
Fractyl Health receives approval for gene therapy diabetes trial By Investing.com - Investing.com Australia
Fractyl Health Receives Approval to Launch First-in-Human Gene Therapy Clinical Trial for Type 2 Diabetes in the Netherlands 1 - Minichart
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial - BioPharma Dive
Fractyl Health Advances RJVA-001 Gene Therapy Trial - TipRanks
Fractyl Health receives approval for gene therapy diabetes trial - Investing.com
Fractyl Health (NASDAQ: GUTS) wins OK for first-in-human RJVA-001 gene therapy trial - Stock Titan
Fractyl Health Authorized to Initiate First-in-Human Trial - GlobeNewswire
Fractyl Health Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference - The Manila Times
Fractyl Health to Report First Quarter 2026 Financial - GlobeNewswire
GUTS Stock Price, Quote & Chart | FRACTYL HEALTH INC (NASDAQ:GUTS) - ChartMill
Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Down 34.7% in April - MarketBeat
Fractyl Health, Inc. (GUTS) loses 77.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Why did GUTS stock plummet today despite positive gut therapy midterm study? - MSN
Fractyl Health plummets on data for Revita for weight loss maintenance - MSN
Fractyl Health Inc (GUTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):